I am a 67-year-old male with generally good vision. I have had a few floaters in my eyes over the years, but they have generally been small ...

FH is a genetic condition of very high cholesterol levels that presents a high risk for coronary artery disease.

I am a 69-year-old woman who was diagnosed with familial hypercholesterolemia (FH). I used statins for over a decade but developed vulvar lichen sclerosus (LS), which only went ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam” or the "Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

non-intensive statin) analysis. Results: The data of 179 patients receiving statins and/or ezetimibe, 50 of which with evolucumab and 129 without, were analyzed. Evolocumab add-on therapy over six ...

In the one completed outcomes trial to date – the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial – in aortic stenosis patients, ezetimibe plus statin therapy did not reduce the ...

In SHARP, a randomized trial, investigators compared simvastatin plus ezetimibe with placebo. Of the 9270 patients (age, ≥40; mean age, 62; 63% men) with chronic kidney disease and no histories ...

Patients were stratified by exposure to statin therapy, ezetimibe, and proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9i mAb). The study assessed LLT adherence (proportion of ...